Drug intelligence / Profile preview

clofarabine + cyclophosphamide + alemtuzumab

Development stage: Preclinical
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of clofarabine (a purine nucleoside antimetabolite), cyclophosphamide (an alkylating agent), and alemtuzumab (a monoclonal antibody targeting CD52). This combination is used in the treatment of relapsed or refractory leukemia, particularly in cases where standard therapies have failed. Each component has a distinct mechanism of action: clofarabine interferes with DNA synthesis and repair, cyclophosphamide damages DNA by forming cross-links, and alemtuzumab targets CD52-expressing lymphocytes causing cell death through antibody-dependent cellular cytolysis and complement-mediated lysis.

Brand names: ClolarCytoxanCampath
Other names: Clofarabine/Cyclophosphamide/Alemtuzumab regimenClofarabine, Cyclophosphamide, and Alemtuzumab conditioning regimenl-Milton S. Hershey Medical Center-leukemia-myelodysplastic syndrome-lymphoma-multiple myeloma

Targets

DNA polymerase familyCD52 (CD52 Antigen)RNR (Ribonucleotide reductase)DNA

Beyond the preview

Go deeper on clofarabine + cyclophosphamide + alemtuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clofarabine + cyclophosphamide + alemtuzumab.

Explore the full profile